Tom Snyder Email & Phone Number

Los Angeles, CA, US

Thousand Oaks, CA, US

Thousand Oaks, CA, US

As leadership development assignment, serving as Chief of Staff for VP of US Value & Access (~250 FTEs). Responsible for day-to-day operations and capability builds (budget, headcount & talent, training & development, process excellence), strategic planning including long range scenarios, and program management. Since joining, managed several strategic.

Thousand Oaks, CA, US

Leading Global Value & Access Strategy for pipeline and launches including LUMAKRAS (KRAS G12C). Interim VP of Global Value & Access in 1H 2021 (150 staff in Access, Pricing, Health Economics, and Policy).

Thousand Oaks, CA, US

Led Value & Access Strategy for oncology pipeline: LUMAKRAS (KRAS G12C), bemarituzumab (FGFRb2), bispecific T-cell engagers.

Thousand Oaks, CA, US

Global Value & Access lead for Immuno-Oncology and Inflammation, and launch of EVENITY (romosozumab) for post-menopausal osteoporosis.

Chicago, IL, US

Drove new business development, delivery, and thought leadership for a life sciences consulting firm (Promidian). Created launch plans to prepare biotechs for their first commercial launches of CAR-Ts in the US.

Lawrence Township, NJ, US

Led all access activities supporting launch of anti-PD1 OPDIVO (nivolumab) in non-small cell lung cancer globally, and access strategy and value evidence generation for anti-IL6 in rheumatoid arthritis.

Nuremberg, Bavaria, DE

Direct global market access strategy engagements, pricing research (payer, physician, and patient), and payer value message development for biotechs and pharmaceutical clients.

Durham, North Carolina, US

Led US Pricing and Market Access practice. Developed launch plan for a dual-brand biologic in multiple sclerosis and leukemia. Published evidence reviews informing Medicare coverage of EPOGEN and ARANESP.

London, England, GB

Led global marketing strategies and tactics to communicate value proposition of products, portfolio, and services to C-suite decision-makers.

London, England, GB

Secured positive coverage, coding, and payment decisions for surgical care products and DME. Developed business plans and value propositions in collaboration with marketing and sales leaders. Led due diligence for licensing and acquisition opportunities. Representative to trade associations and liaison to patient advocacy and lobbying activities.

Dublin 2, IE

Provided strategic consulting support for implementation of Part D payment mechanisms; program management for joint medical/marketing initiatives, pharmaceutical/not-for-profit partnerships, and managed markets analytic support; managed analysts and consultants.

Durham, North Carolina, US

Secured favorable coverage, coding, and payment decisions for client's biopharmaceutical therapies; identified optimal distribution strategies, pricing, sales force training needs, and reimbursement support (hotlines and patient assistance) to support product launches; interacted with CMS and Carrier Medical Directors on behalf of clients; direct reports.

Educated CMS on costs of blood products and advanced clinical diagnostics; advocated with CMS for favorable coverage, coding, and payment of blood products, plasma derivative therapies, and transfusion services; educated hospital and blood bank executives on coding, billing, and cost reporting for transfusion medicine services.

Washington, District Of Columbia, US

Conducted best-practice research into hospital operations and service line strategy; managed teams of analysts and consultants.

Ma, English

Ba, English